Effects of switching from twice-daily tacrolimus to once-daily extended-release meltdose tacrolimus on cellular immune response.

ABSTRACT:

Background

LCP-Tacro [LCPT], a novel once-daily, extended-release formulation of tacrolimus, has a reduced C_max with comparable AUC exposure, requiring a ∼30% dose reduction in contrast to immediate-release tacrolimus (IR-Tac). Once-daily LCPT in de novo kidney transplantation has a comparable efficacy and safety profile to that of IR-Tac with advantages in bioavailability and absorption. The present investigation intends to analyze the effects of conversion from IR-Tac to LCPT on phenotype and function of T-cells and B-cells.

Methods

16 kidney transplant patients treated by triple standard immunosuppression with a stable graft function undergoing a switch from IR-Tac to LCPT were included in this observational prospective study. We measured the main immune

SUBMITTER: Anft M 

PROVIDER: S-EPMC11461451 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature